Noticias y eventos de GeoVax Labs Inc (GOVX)

$0.606

-0.026 (-4.24%)Al cierre

Noticias de GOVX

8.505-26stocktwits

GeoVax Shifts Focus to Vaccine and Cancer Therapies Amid Stock Resale

2.005-26NASDAQ.COM

Biotech Stocks Surge with Akari Leading the Rally

2.005-22NASDAQ.COM

Multiple Companies Experience Significant Stock Price Gains

8.505-19stocktwits

GeoVax Vaccine Development Gains Regulatory Support

4.502-13Benzinga

U.S. Stocks Decline in Morning Trade as Inflation Rate Eases

9.501-09Benzinga

Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%

4.512-19Benzinga

Dow Rises by More Than 200 Points; Conagra Stock Declines Following Q2 Earnings Report

8.510-17SeekingAlpha

GeoVax Labs Seeks Approval to Offer 11.9 Million Shares of Common Stock for Shareholders

1.009-23Globenewswire

Live Stream Registration Now Open for Day 2 of the Emerging Growth Conference 86 on September 25

1.008-18Globenewswire

Join the Live Stream of Day 1 at the Emerging Growth Conference 85 on August 20; Registration Now Open

Ver más noticias

Eventos de GOVX

6/26 14:00

CDC Raises Response Level to Ebola Outbreak in Congo

The Centers for Disease Control raised its response to the Ebola outbreak in the Democratic Republic of Congo to its highest level on Friday , but said the risk of Ebola's spread in the U.S. remained low, reported Reuters. Companies working on Ebola testing and defense solutions include NanoViricides (NNVC), GeoVax Labs (GOVX) and Co-Diagnostics (CODX).

6/12 13:30

HHS Supports Development of Bundibugyo Ebola Vaccine

The HHS ASPR account on X stated: "BARDA is supporting development of Bundibugyo ebolavirus vaccine candidates through the Rapid Response Partnership Vehicle Consortium. We're interested in candidates that leverage the vesicular stomatitis virus platform, which has proven to require just one dose to provide protection for other filoviruses." Vaccine developers include GeoVax Labs (GOVX), Soligenix (SNGX) and Moderna (MRNA).

5/26 10:30

GeoVax Labs Prioritizes Development of GEO-MVA and Gedeptin

GeoVax Labs announced earlier today a strategic prioritization of its development portfolio to concentrate resources on its lead programs, GEO-MVA and Gedeptin. As part of this decision, the company has elected to discontinue development activities related to its GEO-CM04S1 COVID-19 vaccine candidate. "This decision was not related to any safety concerns with the vaccine but reflects the continued evolution and contraction of the global COVID-19 vaccine market, and GeoVax's focus on programs with clearer regulatory pathways, stronger demand visibility, and more immediate commercialization potential," the company said in a statement. It added, "As GEO-MVA advances toward clinical validation and potential commercialization, and as Gedeptin gains relevance within emerging immuno-oncology treatment paradigms, we are aligning our resources to support focused execution against these high-potential opportunities." GEO-MVA is GeoVax's modified vaccinia ankara vaccine candidate targeting mpox and smallpox, which is advancing under an expedited regulatory pathway supported by European Medicines Agency scientific advice.

5/26 10:30

GeoVax Stops COVID Vaccine Development, Stock Drops 11% to $3.24

GeoVax drops 11% to $3.24 after stopping COVID vaccine development

5/26 09:10

GeoVax Labs Files to Sell 7.64M Shares of Common Stock

GeoVax Labs files to sell 7.64M shares of common stock for holders

Ver más eventos

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.